Antibodies for bioanalysis and drug monitoring of bevacizumab and biosimilars

Develop highly selective and sensitive PK assays for bevacizumab (Avastin) and ADA assays for bevacizumab and ranibizumab using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to bevacizumab and ranibizumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Bevacizumab and Ranibizumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Bevacizumab

Inhibitory

Type 1

HCA182

AbD17976

Fab-V5Sx21

0.4

PK bridging ELISA

Order HCA182

HCA184
HCA184P

AbD16748_hIgG1

hIgG1

HRP

2.1

PK bridging ELISA

Order HCA184
Order HCA184P

Bevacizumab

Ranibizumab2

Inhibitory

Type 1

HCA185

AbD17976_hIgG1

hIgG1

0.4

ADA control

Order HCA185

* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody, V5- and StrepX-StrepX- tags

2 Ranibizumab originates from the same parental mouse antibody as bevacizumab; it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab


Anti-Bevacizumab Inhibitory Antibodies (Type 1)

Type 1 anti-bevacizumab antibodies inhibit the binding of the drug bevacizumab to its target, vascular endothelial growth factor, VEGF. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay for both bevacizumab and ranibizumab.


ELISA Protocols to Get You Started

PK Bridging ELISA


PK bridging ELISA using antibodies HCA182 and HCA184P

Fig. 1. Bevacizumab PK bridging ELISA using antibodies HCA182 and HCA184P.

Pharmacokinetic (PK) Assay - Bridging Format

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA


Figure 2: Immunogenicity assay, bridging ELISA format

Fig. 2. Bevacizumab ADA bridging ELISA using antibody HCA185.

Immunogenicity Assay – Bridging Format

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).



Fig. 3. Ranibizumab ADA bridging ELISA using HCA185.

Fig. 3. Ranibizumab ADA bridging ELISA using HCA185.

Schematic image of PK Bridging ELISA. Capture antibody, Fab format (purple), fusion protein drug (gold-green), detection antibody, Ig format (blue), labeled with HRP

Schematic image of ADA bridging assay. Monoclonal Fab fragment antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).



Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.